Ribose (Furanose)

Ribose (Furanose)

SCHEMBL447758

OC[C@@H]1OC(O)[C@H](O)[C@H]1O

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LGALS1 P09382 2/20 0.54
LGALS3 P17931 2/20 0.54
LGALS9 O00182 1/20 0.54
LGALS8 O00214 1/20 0.54
LMNA P02545 3/20 0.44
ALDH1A1 P00352 2/20 0.44
TSHR P16473 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
CA12 O43570 3/20 0.42
CA1 P00915 3/20 0.42
CA2 P00918 3/20 0.42
CA9 Q16790 3/20 0.42
KDM4E B2RXH2 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C19 P33261 1/20 0.42
GBA1 P04062 1/20 0.41
PYGB P11216 4/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ribose (Furanose) SCHEMBL15814845 1.00 LGALS1 (0.54) LGALS1LGALS3LGALS9LGALS8LMNA
Ribose (Furanose) SCHEMBL14349491 1.00 LGALS1 (0.54) LGALS1LGALS3LGALS9LGALS8LMNA
Ribose (Furanose) SCHEMBL16199379 1.00 LGALS1 (0.54) LGALS1LGALS3LGALS9LGALS8LMNA
Ribose (Furanose) SCHEMBL24087736 1.00 LGALS1 (0.54) LGALS1LGALS3LGALS9LGALS8LMNA
Ribose (Furanose) SCHEMBL66645 1.00 LGALS1 (0.54) LGALS1LGALS3LGALS9LGALS8LMNA
Ribose (Furanose) SCHEMBL23017520 1.00 LGALS1 (0.54) LGALS1LGALS3LGALS9LGALS8LMNA
Ribose (Furanose) SCHEMBL109435 1.00 LGALS1 (0.54) LGALS1LGALS3LGALS9LGALS8LMNA
Ribose (Furanose) SCHEMBL12878699 1.00 LGALS1 (0.54) LGALS1LGALS3LGALS9LGALS8LMNA
Ribose (Furanose) SCHEMBL7618455 1.00 LGALS1 (0.54) LGALS1LGALS3LGALS9LGALS8LMNA
Ribose (Furanose) SCHEMBL13135754 1.00 LGALS1 (0.54) LGALS1LGALS3LGALS9LGALS8LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 999 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-121005799-B Application of uncaria neutral polysaccharide URP-W in preparation of glioma resistant drugs CHANGCHUN UNIVERSITY OF CHINESE MEDICINE (CN) 2026-05-26 CN claimed
CN-122080245-A Novel polysaccharide extracted from dark plum fruit, and preparation method and application thereof 2026-05-26 CN claimed
CN-122036983-A Nine-steaming nine-preparation rhizoma polygonati uniform polysaccharide and preparation method and application thereof 黑龙江省中医药科学院 2026-05-15 CN claimed
CN-122036977-A Tibetan angelica uniform polysaccharide and preparation method and application thereof 陕西中医药大学 2026-05-15 CN claimed
CN-122036980-A Uniform polysaccharide, preparation method thereof and application thereof in improving glycolipid metabolic disorder 浙江中医药大学 2026-05-15 CN claimed
CN-122011233-A Ampelopsis polysaccharide, preparation method thereof and application of Ampelopsis polysaccharide in preparation of colorectal cancer therapeutic drugs 浙江工业大学 2026-05-12 CN claimed
EP-4701656-A1 IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS AND USES THEREOF Pfizer Inc. (US) 2026-03-04 EP claimed
US-20250302947-A1 M-cell GP2-mediated lymphatic-targeted drug carriers HONG KONG BAPTIST UNIVERSITY (CN) 2025-10-02 US claimed
CN-120157783-A Litchi chitin and extraction method and application thereof 贵州中医药大学 2025-06-17 CN claimed
CN-117467031-B Lalang grass rhizome acidic polysaccharide, preparation method and application 东北林业大学 2025-05-27 CN claimed
US-20040063612-A1 Neuroprotective agents CARBOMER, INC. 2004-04-01 US claimed
EP-1373288-A1 PROCESS FOR THE PREPARATION OF 2'-HALO-BETA-L-ARABINOFURANOSYL NUCLEOSIDES Triangle Pharmaceuticals Inc. (US) 2004-01-02 EP claimed
US-20030060622-A1 Process for the preparation of 2'-halo-beta-L-arabinofuranosyl nucleosides BUKWANG PHARMACEUTICAL IND CO., LTD. (KR) 2003-03-27 US claimed
WO-2002079213-A1 PROCESS FOR THE PREPARATION OF 2'-HALO-$G(B)-L-ARABINOFURANOSYL NUCLEOSIDES TRIANGLE PHARMACEUTICALS, INC. (US) 2002-10-10 WO claimed
WO-1999006584-A1 THERMOSTABLE ALPHA-L-ARABINOFURANOSIDASE FROM AUREOBASIDIUM PULLULANS THE UNITED STATES OF AMERICA REPRESENTED BY THE (US) 1999-02-11 WO claimed
EP-0475383-B1 Polysaccharide composition or polysaccharide having heparinoid activity, process for producing the same, and anticoagulant containing the same as active ingredient NISSHIN SPINNING (JP) 1995-12-06 EP claimed
US-5268366-A Polysaccharide composition or polysaccharide having heparinoid activity, process for producing the same, and anticoagulant containing the same as active ingredient NISSHINBO INDUSTRIES, INC. (JP) 1993-12-07 US claimed
US-5185327-A Glucan derivatives having tumoricidal activity AJINOMOTO COMPANY, INC. (JP) 1993-02-09 US claimed
EP-0475383-A2 Polysaccharide composition or polysaccharide having heparinoid activity, process for producing the same, and anticoagulant containing the same as active ingredient NISSHINBO INDUSTRIES, INC. (JP) 1992-03-18 EP claimed
US-4973581-A GALACTOPYANOSE OR ARABINOFURANOSE SIDE CHAIN AJINOMOTO COMPANY, INC. (JP) 1990-11-27 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030060622-A1 Process for the preparation of 2'-halo-beta-L-arabinofuranosyl nucleosides FUCA2, FUCA1, GALE LGALS1 426/4885LGALS3 388/4885LGALS9 285/4885
US-20040063612-A1 Neuroprotective agents GAP43, NLN, NOS3 LGALS1 2328/4885LGALS3 1892/4885LGALS9 2729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.